Table 4.

Correlation of clinicopathologic findings with tumor PD-Ls expression and TIL counts

CharacteristicsPD-L1
PD-L2
CTLs
Treg
LowHighPLowHighPLowHighPLowHighP
Age, y
    ≤5292320.7792320.7770540.05358660.24
    >528828882851656353
Gender
    Male155490.40152520.681041000.68107970.13
    Female251128817191422
Hepatitis history
    Yes168561.00169550.551151090.291111130.32
    No124115610106
α-Fetoprotein (ng/mL)
    ≤2067150.08462200.8843390.6554280.001
    >20113451184078806791
γ-Glutamyl transferase (units/L)
    ≤5477270.7682220.2345590.05358460.15
    >5410333983876606373
Liver cirrhosis
    Yes158540.64158540.641011110.0181011110.018
    No226226208208
Tumor size (cm)
    ≤591260.3389280.7152650.07158590.80
    >58934913269546360
Tumor encapsulation
    None87340.2688310.7149700.00556650.20
    Complete9326922972496554
Tumor multiplicity
    Single138461.00140440.4888960.15102820.005
    Multiple4214401633231937
Tumor differentiation
    I-II106290.15100350.7162730.1277580.020
    III-IV7431802559464461
Vascular invasion
    Yes75340.04371380.00155760.00445640.010
    No105261092266437655
TNM stage
    I84220.4088180.03845610.00968380.001
    II5422522437392848
    III4216401839192533
Adjuvant therapy
    None63190.8461220.1241410.9442400.017
    TACE9434923664645771
    Immunotherapy *2372731614228
Postrecurrent therapy
    None20110.832740.1218130.3415160.013
    TACE3519342031231539
    Regional31314031
    Resection1031037694
  • NOTE: Pearson's χ2 test.

  • * Cytokine-based immunotherapy, such as IFN-α and interleukin-2.

  • Radiofrequency ablation and percutaneous ethanol injection.